New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 25, 2014
14:02 EDTCNCEConcert Pharm says phase 2 trial of CTP-499 did not meet primary endpoint
News For CNCE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
09:02 EDTCNCEConcert Pharmaceuticals 500K share Block Trade priced at $12.55
The deal range was $12.42-$12.55. UBS acted as sole book running manager for the offering.
November 12, 2014
08:22 EDTCNCEConcert Pharma to delay initiation of planned CTP-354 Phase 2 clinical trials
Based upon preliminary findings from an ongoing three-month non-clinical study with CTP-354, the company has today announced its decision to delay the initiation of its planned CTP-354 Phase 2 clinical trials. Concert intends to conduct additional non-clinical studies to further characterize CTP-354 and assess its development profile. The Company had previously planned to initiate a Phase 2 program in 2014 in parallel with the ongoing non-clinical evaluation. CTP-354 is being developed as a potential non-sedating treatment for spasticity in patients with spinal cord injury and with multiple sclerosis.
08:21 EDTCNCEConcert Pharmaceuticals reports Q3 EPS (43c), consensus (49c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use